LMND heads into the week with a contradictory setup: short sellers are quietly covering while options traders have shifted to their most bullish posture in months — yet the stock is still down 8% on the week and insiders keep selling.
The positioning story is the most interesting angle right now. Short interest has fallen for four consecutive sessions, dropping nearly 4% on the week to 13.9% of the free float — still a heavy structural short, but the direction of travel is clearly toward covering. The borrow market offers no friction for new shorts: availability is loose at 389%, well above even the 52-week tightest reading of 134%, and cost to borrow remains negligible at 0.47%. There is no squeeze dynamic here. What makes the positioning picture genuinely unusual is the options data. The put/call ratio has dropped to 0.60, two full standard deviations below its 20-day average of 0.65 — the most call-heavy reading in months, and close to the lowest ratio of the past year. Options traders are leaning bullish at the same moment shorts are retreating. That divergence is worth watching.
The Street is sending mixed messages. Bulls — led by Morgan Stanley's Overweight, a $75 target (trimmed from $80 in May), and Citizens at $80 — see the AI-driven insurance model growing into its valuation. Truist also holds a Buy, though cut its target sharply to $70 from $98 after the Q1 print. Sceptics point to persistent losses: the EV/EBITDA multiple is deeply negative at -262x, price-to-book has compressed to 8.5x from above 9x over the past month, and the consensus is officially a sell. The mean price target of $62 implies roughly 16% upside from the current $53.58, but that figure is dragged higher by a few bullish outliers — KBW maintains an Underperform with a $44 target. Factor scores reinforce the bear case: EPS momentum ranks in the 3rd percentile over both 30-day and 90-day windows, and the short score of 63 places LMND firmly in the elevated-risk zone.
Insider activity this week leans cautious. The CFO Timothy Bixby and two other executives sold shares at around $53 on June 3rd — small in absolute dollar terms (under $200k combined) but consistent with a pattern of regular sell-side activity from management. The net 90-day insider flow is technically positive at around $952k, reflecting a director purchase back in March, but the recent cluster of sales near current prices is not a ringing endorsement. JP Morgan Asset Management added 347k shares as of late May, one of the more notable institutional moves in recent filings.
Earnings history adds another layer of caution. The last two quarterly prints produced sharp one-day moves of -11% and -14% respectively. The next event is July 29. With cost-to-borrow still low and availability abundant, there is no mechanical squeeze pressure ahead of that date — but the combination of a 14% free-float short position and a history of double-digit post-earnings drops means the setup into Q2 results will bear close watching, particularly if the current options skew toward calls continues to build.
Peer context is moderately constructive: ROOT fell 3.4% on the week and HIPO dropped 2.6%, while LMND's 7.7% decline looks sharper — but the stock recovered 1.2% on Tuesday, suggesting sellers may be running thin at these levels. The central question into July is whether the covering in short interest and the call-side options tilt reflect genuine re-rating conviction, or simply tactical positioning ahead of a volatile earnings date.
See the live data behind this article on ORTEX.
Open LMND on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
